Knight Therapeutics Inc. reconfirmed earnings guidance for the year 2024. Knight expects to generate between $335 million to $350 million in revenues.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 CAD | -0.49% | +2.86% | +17.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.73% | 455M | |
+15.58% | 79.03B | |
+10.49% | 8.96B | |
-10.76% | 5.19B | |
+54.31% | 4.77B | |
+11.19% | 4.26B | |
-22.37% | 2.37B | |
+12.49% | 2.3B | |
-30.09% | 2.21B | |
+20.63% | 2.17B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024